Related Articles
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors